Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

According to Stifel, the Meta partnership positions EssilorLuxottica at the forefront of the smart glasses revolution. The ...

Stifel Financial Corp. (NYSE: SF) will release its fourth quarter and full year 2024 financial results before the market opens on Wednesday, January 29, 2025. The company will host a conference call ...

Stifel analyst Johannes Braun downgraded Air France-KLM (AFLYY) to Hold from Buy with a price target of EUR 8, down from EUR 13. The company’s ...

Thursday, January 23, 2025, marks the release of a new report by Stifel analysts on the US transport sector. The report outlines a cautious perspective on the industry's future, noting that while 2024 ...

Stifel analyst Brian Brophy raised the firm’s price target on Quanta Services (PWR) to $388 from $374 and keeps a Buy rating ...

CEO Ron Kruszewski and Yahoo Finance Executive Editor Brian Sozzi at the 2025 World Economic Forum in Davos, Switzerland, to talk about the macro issues impacting the investment banking firm, ...

Stifel analysts reiterated their Hold rating on Texas Instruments stock (NASDAQ:TXN) with a steady price target of $200.00.

Plby Group Inc (PLBY) stock saw a decline, ending the day at $1.81 which represents a decrease of $-0.04 or -2.16% from the prior close of $1.85. The stock opened at $1.84 and touched a low of $1.72 ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

In recent trading, shares of Stifel Financial Corp (Symbol: SF) have crossed above the average analyst 12-month target price of $116.00, changing hands for $116.23/share. When a stock reaches the ...